TheAnswerPage

MAY 23, 2022

For what health conditions is the therapeutic applicability of CBD being evaluated? The range of conditions for which CBD has been (or is being) assessed is quite diverse. Clinicaltrials.gov. See the Answer.

Clinical Trials 45

Clinical Trials Conditions CBD 45

Cannabis Law Report

AUGUST 14, 2021

After acquiring the patented Gelpell technology through its acquisition of Satipharm in March, Cann is now looking to resume an internal development program with the aim of securing TGA approval for a Schedule 3 CBD product by the end of 2022.

CBD 105

CBD Clinical Trials Programs Medicine 105

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. Conference Call and Webcast Details.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

TheAnswerPage

JUNE 29, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 45

Clinical Trials Epilepsy Pharmaceutical Treatment 45

TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 45

Clinical Trials Epilepsy Pharmaceutical Treatment 45

Cannabis Law Report

JULY 25, 2022

million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Veriheal

APRIL 18, 2022

According to the 2022 study published in the journal Drug and Alcohol Dependence, researchers found that smoking cannabis accelerates the biological aging process. Unfortunately, research on cannabis and aging remains limited but its benefits for aging can be seen through existing research on medical conditions associated with getting older.

Research and Development 98

Research and Development Clinical Trials Conditions Cannabis 98

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. June 14, 2022 02:00 AM Eastern Daylight Time. However, we need rigorous clinical trials to ensure that this promise is realised.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

The Cannigma

MAY 13, 2022

There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. 5 best desktop vaporizers for weed in 2022. When dealing with pain, the presence of THC is often most helpful to patients with painful conditions, so a type I or type II strain is often preferred. Related Stories.

Terpenes 111

Terpenes Strains Chronic Pain Clinical Trials 111

Veriheal

MAY 2, 2022

Of all the diseases and medical conditions that humans face the risk of being diagnosed with—even people who lead the healthiest of lifestyles—cancer is one of the most prevalent and deadly. Plus, a large-scale British trial of GW Pharmaceuticals’ cannabis-based drug Sativex was believed to have kicked off in March 2022.

Treatment 98

Treatment Clinical Trials Patients Medicine 98

Cannabis Law Report

MAY 10, 2022

11 May 2022. Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. First comprehensive study reveals why Australians take medicinal cannabis.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JANUARY 3, 2022

Affirms expectations for initial topline results in 1H 2022. regulatory path; company expects to submit IND in 1Q 2022. We continue to anticipate reporting initial topline results from Part A of this trial in the first half of 2022, as we closely monitor the impact of COVID-19. Chief Executive Officer of Anebulo.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

OCTOBER 9, 2021

A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder (PTSD)—the latest example of how the psychedelics reform movement is gaining momentum. Led by Rep. MEMORANDUM.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

The Cannigma

DECEMBER 12, 2022

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). May 11, 2022 02:00 AM Eastern Daylight Time. Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

MARCH 16, 2022

March 15, 2022 /CNW/ – PsyBio Therapeutics Corp. The PsyBio team has extensive experience in drug discovery and development based on synthetic biology, metabolic engineering, medicinal chemistry and clinical pharmacology, as well as clinical and regulatory expertise progressing drugs through human studies and governmental protocols.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Medicine 52

Cannabis Law Report

JANUARY 4, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

APRIL 21, 2022

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC is a Public Benefit Corporation, with a dual mandate to generate shareholder value and public benefit. Key Responsibilities.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

NOVEMBER 29, 2021

Treatment-resistant depression – meaning patients have tried everything possible and did not find relief – is a harrowing condition affecting one in three people with depression – that’s a staggering one hundred million people worldwide for whom current depression treatments just don’t work. TRD is just the beginning.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. Financial Results.

Clinical Trials 40

Clinical Trials Research and Development Treatment Data 40

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. In the US, hopes of a quick federal cannabis legalisation in 2022 are fading, but a long shot such as cannabis having a major impact on COVID transmission or remission could speed things up.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

JANUARY 5, 2022

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. The patent will be issued on January 11, 2022. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.”

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. IGC may not be able to complete human trials on our investigational drug candidates, or, once conducted, the results of human trials testing may not be favorable or as anticipated.

Clinical Trials 40

Clinical Trials Research and Development Data Business 40

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

SpeedWeed

AUGUST 4, 2021

Due to largely changing environmental conditions during the cultivation process, most cannabis companies have not been able to achieve accuracy and consistency of finished flower medicines. Through collaboration with industry in Australia, MCA products will become available to the global market in early 2022. View original article.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 40

Therapy Research and Development Business Access 40

Project CBD

FEBRUARY 27, 2023

Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. It’s not a new idea.

THC 144

THC CBD Clinical Trials Sleep 144

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JANUARY 12, 2022

11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. LAS VEGAS, Jan.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. Draft Law of Ukraine. ARV (revised). REFERENCE to the EU acquis. explanatory note. Comparative table. LAW OF UKRAINE.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

DECEMBER 21, 2021

Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. It’s also initiating phase 2a clinical trial into conditions such as eating disorders and fibromyalgia.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

NOVEMBER 12, 2021

As set out above, the Company understands that Brown Shipley is unable to exercise its security over the Pledged Shares until 1 July 2022 and has been informed that KCP are in discussions with Brown Shipley about removing the Pledged Shares from the Charge and will update the market accordingly. A PDMR form is set out below. 198,466,493.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98